BACKGROUND: Peri-operative coagulation management of patients receiving apixaban, a new oral anticoagulant, is difficult. The CytoSorb® hemoadsorption device might represent a therapeutic option to reduce apixaban's pharmacological and inflammatory effects during high-risk surgery. CASE PRESENTATION: An 83-year-old woman treated with Apixaban underwent emergent redo mitral valve replacement for prosthetic valve endocarditis. A CytoSorb® cartridge was added to the cardio-pulmonary bypass (CPB) circuit. Apixaban-specific anti-factor Xa activity (AFXaA) were measured peri-operatively. After 100 minutes of CPB, a 50% AFXaA rate decrease was observed as compared to pre-CPB values. Furthermore, we noticed 39% and 44% reductions of AFXaA levels in comparison to the expected levels in patients with normal or altered renal function, respectively. CONCLUSION: Insertion of a CytoSorb® cartridge in the CPB was safe and associated with rapid correction of Apixaban-associated anticoagulation.
BACKGROUND: Peri-operative coagulation management of patients receiving apixaban, a new oral anticoagulant, is difficult. The CytoSorb® hemoadsorption device might represent a therapeutic option to reduce apixaban's pharmacological and inflammatory effects during high-risk surgery. CASE PRESENTATION: An 83-year-old woman treated with Apixaban underwent emergent redo mitral valve replacement for prosthetic valve endocarditis. A CytoSorb® cartridge was added to the cardio-pulmonary bypass (CPB) circuit. Apixaban-specific anti-factor Xa activity (AFXaA) were measured peri-operatively. After 100 minutes of CPB, a 50% AFXaA rate decrease was observed as compared to pre-CPB values. Furthermore, we noticed 39% and 44% reductions of AFXaA levels in comparison to the expected levels in patients with normal or altered renal function, respectively. CONCLUSION: Insertion of a CytoSorb® cartridge in the CPB was safe and associated with rapid correction of Apixaban-associated anticoagulation.
Authors: Joerg Scheier; Peter J Nelson; Antoine Schneider; Sébastien Colombier; Detlef Kindgen-Milles; Efthymios N Deliargyris; Thomas D Nolin Journal: Crit Care Explor Date: 2022-05-09
Authors: Christina Scharf; Ferdinand Weinelt; Ines Schroeder; Michael Paal; Michael Weigand; Michael Zoller; Michael Irlbeck; Charlotte Kloft; Josef Briegel; Uwe Liebchen Journal: Ann Intensive Care Date: 2022-05-23 Impact factor: 10.318
Authors: Marijana Matejic-Spasic; Kambiz Hassan; Matthias Thielmann; Stephan Geidel; Robert F Storey; Michael Schmoeckel; Harriet Adamson; Efthymios N Deliargyris; Daniel Wendt Journal: J Thorac Dis Date: 2022-08 Impact factor: 3.005
Authors: Kambiz Hassan; Matthias Thielmann; Jerry Easo; Markus Kamler; Daniel Wendt; Zaki Haidari; Efthymios Deliargyris; Mohamed El Gabry; Arjang Ruhparwar; Stephan Geidel; Michael Schmoeckel Journal: J Clin Med Date: 2022-10-05 Impact factor: 4.964